IQVIA Holdings Inc (IQV)vsRadNet Inc (RDNT)
IQV
IQVIA Holdings Inc
$165.64
-0.27%
HEALTHCARE · Cap: $28.11B
RDNT
RadNet Inc
$60.66
+1.32%
HEALTHCARE · Cap: $4.65B
Smart Verdict
WallStSmart Research — data-driven comparison
IQVIA Holdings Inc generates 699% more annual revenue ($16.31B vs $2.04B). IQV leads profitability with a 8.3% profit margin vs -0.9%. RDNT appears more attractively valued with a PEG of 0.96. IQV earns a higher WallStSmart Score of 72/100 (B).
IQV
Strong Buy72
out of 100
Grade: B
RDNT
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+49.1%
Fair Value
$348.46
Current Price
$165.64
$182.82 discount
Intrinsic value data unavailable for RDNT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 21 in profit
Growing faster than its price suggests
Earnings expanding 23.6% YoY
Earnings expanding 75.0% YoY
Growing faster than its price suggests
Areas to Watch
Distress zone — elevated risk
ROE of 1.4% — below average capital efficiency
Weak financial health signals
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : IQV
The strongest argument for IQV centers on Return on Equity, PEG Ratio, EPS Growth. Revenue growth of 10.3% demonstrates continued momentum. PEG of 0.97 suggests the stock is reasonably priced for its growth.
Bull Case : RDNT
The strongest argument for RDNT centers on EPS Growth, PEG Ratio. Revenue growth of 14.8% demonstrates continued momentum. PEG of 0.96 suggests the stock is reasonably priced for its growth.
Bear Case : IQV
The primary concerns for IQV are Altman Z-Score.
Bear Case : RDNT
The primary concerns for RDNT are Return on Equity, Piotroski F-Score, Free Cash Flow.
Key Dynamics to Monitor
IQV profiles as a value stock while RDNT is a turnaround play — different risk/reward profiles.
RDNT carries more volatility with a beta of 1.46 — expect wider price swings.
RDNT is growing revenue faster at 14.8% — sustainability is the question.
IQV generates stronger free cash flow (561M), providing more financial flexibility.
Bottom Line
IQV scores higher overall (72/100 vs 54/100) and 10.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IQVIA Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
RadNet Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
RadNet, Inc., provides outpatient imaging services in the United States. The company is headquartered in Los Angeles, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?